Aug 23, 2022 / NTS GMT
Presentation
Aug 23, 2022 / NTS GMT
=====================
Corporate Participants
=====================
* René C. Goehrum
BioSyent Inc. - Chairman, CEO & President
=====================
RenéC. Goehrum - BioSyent Inc. - Chairman, CEO & President
Hello, and welcome to the BioSyent Inc. Q2 and First Half 2022 Results Presentation. My name is René Goehrum, and I'm the President and CEO of the company. I want to draw your attention to our disclaimer regarding forward-looking statements.
So let's start the presentation with a look at our sales, EBITDA and net income after tax for the quarter ended June 30. So we've done something here for your comparison. We've taken a look at the business with and without our continuing Canadian pharma brands. We discontinued 2 products -- 3 products, 2 brands at the beginning of this year. When we compare the Canadian pharma business to continuing brands, we're up marginally at plus 1%. If we compare it with including discontinued operations, we're down 6% on the Canadian pharma business. The
Q2 2022 Biosyent Inc Earnings Presentation Transcript
Aug 23, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers